907 reports of this reaction
1.4% of all METHYLPHENIDATE reports
#12 most reported adverse reaction
DISTURBANCE IN ATTENTION is the #12 most commonly reported adverse reaction for METHYLPHENIDATE, manufactured by Noven Therapeutics, LLC. There are 907 FDA adverse event reports linking METHYLPHENIDATE to DISTURBANCE IN ATTENTION. This represents approximately 1.4% of all 63,290 adverse event reports for this drug.
Patients taking METHYLPHENIDATE who experience disturbance in attention should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISTURBANCE IN ATTENTION is a less commonly reported adverse event for METHYLPHENIDATE, but still significant enough to appear in the safety profile.
In addition to disturbance in attention, the following adverse reactions have been reported for METHYLPHENIDATE:
The following drugs have also been linked to disturbance in attention in FDA adverse event reports:
DISTURBANCE IN ATTENTION has been reported as an adverse event in 907 FDA reports for METHYLPHENIDATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISTURBANCE IN ATTENTION accounts for approximately 1.4% of all adverse event reports for METHYLPHENIDATE, making it a notable side effect.
If you experience disturbance in attention while taking METHYLPHENIDATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.